A randomized controlled pilot trial to assess the effectiveness of a specially formulated food supplement and pelvic floor muscle training in women with stress-predominant urinary incontinence.

What Was Tested

The paper reports a study of Copper (Supplement), published as a randomized controlled trial.

Pelvic floor muscle training (PFMT) is the first-line treatment approach for stress urinary incontinence.

Who Took Part

The abstract describes 16 patients taking part.

PubMed tags the participants as women only.

Secondary outcomes were the Incontinence Impact Questionnaire (IIQ-7) score, Patient's Global Impression of Severity (PGI-S), and Biomechanical Integrity score (BI-score) measured by Vaginal Tactile Imager.

How the Study Was Run

In design terms this was a randomized, placebo-controlled and pilot study.

The patients were allocated by chance, so the Copper (Supplement) group and the comparison group should start out alike.

Some patients received a placebo instead of Copper (Supplement), giving a reference point.

It is described as a pilot, a small early test of whether a larger Copper (Supplement) study would be practical.

The primary outcome was the Urogenital Distress Inventory Short Form (UDI-6) score.

What Was Measured

The subject headings attached to it are Urinary Incontinence, Stress, Pelvic Floor, Pilot Projects, Exercise Therapy, Urinary Incontinence and Quality of Life.

The authors tagged it with the keywords Creatine, Leucine and Zinc.

What This Means in Plain Language

The paper is a randomized, placebo-controlled and pilot study of Copper (Supplement) in 16 patients.

With fewer than 40 people, it is a small study, so it is better read as an early signal for further research than as a settled answer.

Results are reported in around 6 sentences of the abstract; we leave them to the paper itself rather than summarise them.

The publication is from 2023 (BMC women's health), a journal based in England.

More context: the Copper (Supplement) compound page, all human trials.